Andrew A. Hindman - 18 Nov 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP, CHIEF FINANCIAL OFFICER
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
18 Nov 2022
Net transactions value
-$988,110
Form type
4
Filing time
22 Nov 2022, 15:07:30 UTC
Previous filing
23 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Sale $716,242 -65,000 -14% $11.02 409,771 18 Nov 2022 Direct F1, F2
transaction TBPH Ordinary Shares Tax liability $271,868 -25,057 -6.1% $10.85 384,714 20 Nov 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2 Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.
F3 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.